カテゴリ： GlobalData, フランス, 企業調査

Laboratoires Pierre Fabre SA：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Laboratoires Pierre Fabre SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3432
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：86
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company’s products address the full spectrum of health care needs from pathologies such as cancer or atopical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands which include Derma, Galenic Klorane, Avene, Ducray, Rene Furterer, and others. Pierre Fabre is headquartered in Ile-de-France, France.

Laboratoires Pierre Fabre SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Partnerships 19
Pierre Fabre Enters into Distribution Agreement with Medinova 19
Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20
Pierre Fabre Expands Agreement with Roche for W0101 21
Pierre Fabre Enters into Agreement with MEME Cosmetics 22
Institut Curie Enters into Agreement with Pierre Fabre 23
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Licensing Agreements 49
Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49
Substipharm Enters into Licensing Agreement with Pierre Fabre 50
Pierre Fabre Enters into Licensing Agreement with Hill Derma 51
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59
Pierre Fabre Enters into Licensing Agreement with Lonza 60
Pierre Fabre Enters into Licensing Agreement with Lonza 61
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63
Pierre Fabre Enters into Licensing Agreement with Medis 64
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65
Pierre Fabre Enters into Licensing Agreement with PLEURAN 66
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72
Equity Offering 73
Pierre Fabre Invests in MEME Cosmetics 73
TargeOn Raises Funds through Private Placement of Shares 74
Asset Transactions 75
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75
Acquisition 76
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 76
Laboratoires Pierre Fabre SA – Key Competitors 77
Laboratoires Pierre Fabre SA – Key Employees 78
Laboratoires Pierre Fabre SA – Locations And Subsidiaries 79
Head Office 79
Other Locations & Subsidiaries 79
Affiliate 82
Recent Developments 83
Corporate Communications 83
May 04, 2018: Pierre Fabre Appoints Eric Ducournau As New Chief Executive Officer 83
Other Significant Developments 84
Jun 15, 2018: Feelcaps, to promote physical activity among cancer patients 84
Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Laboratoires Pierre Fabre SA, Deals By Therapy Area, 2012 to YTD 2018 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Pierre Fabre Enters into Distribution Agreement with Medinova 19
Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 20
Pierre Fabre Expands Agreement with Roche for W0101 21
Pierre Fabre Enters into Agreement with MEME Cosmetics 22
Institut Curie Enters into Agreement with Pierre Fabre 23
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 24
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 25
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 26
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Boston Pharma Enters into Licensing Agreement Laboratoires Pierre 49
Substipharm Enters into Licensing Agreement with Pierre Fabre 50
Pierre Fabre Enters into Licensing Agreement with Hill Derma 51
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 52
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 53
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 54
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 55
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 56
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 57
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 58
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 59
Pierre Fabre Enters into Licensing Agreement with Lonza 60
Pierre Fabre Enters into Licensing Agreement with Lonza 61
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 62
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 63
Pierre Fabre Enters into Licensing Agreement with Medis 64
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 65
Pierre Fabre Enters into Licensing Agreement with PLEURAN 66
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 67
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 68
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 69
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 71
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 72
Pierre Fabre Invests in MEME Cosmetics 73
TargeOn Raises Funds through Private Placement of Shares 74
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 75
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 76
Laboratoires Pierre Fabre SA, Key Competitors 77
Laboratoires Pierre Fabre SA, Key Employees 78
Laboratoires Pierre Fabre SA, Other Locations 79
Laboratoires Pierre Fabre SA, Subsidiaries 80
Laboratoires Pierre Fabre SA, Affiliate 82

List of Figures
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Laboratoires Pierre Fabre SA：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CIRCOR Aerospace Products Group：企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Hess Corporation (HES)-エネルギー分野：企業M&A・提携分析
    Summary Hess Corporation (Hess) is a global independent energy company which carries out the exploration and production of crude oil and natural gas. It primarily operates in US, Denmark, Equatorial Guinea, the Joint Development Area of Malaysia/Thailand (JDA), Malaysia, and Norway. It offers fee-ba …
  • Guardant Health Inc (GH)：企業の製品パイプライン分析2018
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • DiaMedica Therapeutics Inc (DMA)：医療機器：M&Aディール及び事業提携情報
    Summary DiaMedica Therapeutics Inc (DiaMedica), formerly DiaMedica Inc is a clinical-stage biopharmaceutical company which develops innovative medicines for the treatment neurological and kidney diseases. Its lead product candidate DM-199, is a human recombinant protein that treats diabetes type 1 a …
  • FuelCell Energy Inc (FCEL)：電力：M&Aディール及び事業提携情報
    Summary FuelCell Energy Inc (FuelCell Energy) is an integrated fuel cell company that designs, manufactures, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company offers proprietary fuel cell products based on carbonate fuel cell technology. …
  • Takara Holdings Inc.：企業の戦略・SWOT・財務情報
    Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Arkle Resources Plc：企業の戦略・SWOT・財務分析
    Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Inform Genomics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Inform Genomics Inc (Inform Genomics) manufactures and markets genomic-based personalized medicine products for cancer and supportive care. The company’s onpart is a medicinal product, which is used for the treatment of decisions in patients, who receive chemotherapy for colorectal, breast, …
  • Yes Bank Ltd：企業のM&A・事業提携・投資動向
    Yes Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Yes Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Valneva SE (VLA)：企業の財務・戦略的SWOT分析
    Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • DaVita Inc (DVA)：企業の財務・戦略的SWOT分析
    DaVita Inc (DVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • TiGenix NV (TIG)：企業の財務・戦略的SWOT分析
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • United BioPharma Inc (6471)：製薬・医療：M&Aディール及び事業提携情報
    Summary United BioPharma Inc (United BioPharma) is a pharmaceutical company. The company develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies. Its molecules product pipeline includes UB-421, a monoclonal antibody for AIDS treatment; and UB-621, an anti-her …
  • Smiths Group Plc (SMIN)：企業の財務・戦略的SWOT分析
    Smiths Group Plc (SMIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Exact Imaging Inc：医療機器：M&Aディール及び事業提携情報
    Summary Exact Imaging Inc (Exact Imaging) formerly Imagistx Inc, is a provider of high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies for prostate cancer analysis. The company’s ExactVu micro-ultrasound platform operates high resolution conventional and biopsy tra …
  • U.S. Smokeless Tobacco Company：企業の戦略・SWOT・財務分析
    U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report Summary U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Sanquin Blood Supply Foundation：医療機器：M&Aディール及び事業提携情報
    Summary Sanquin Blood Supply Foundation (Sanquin) is a provider of blood bank and diagnostic services, plasma derived products, tissues and cells and reagents. It offers blood-related lab tests for hospitals, blood banks, obstetricians practices, pharmaceutical companies, insurance organizations, an …
  • Eolus Vind AB (EOLU B)：企業の財務・戦略的SWOT分析
    Summary Eolus Vind AB (Eolus Vind) is a wind farm developer that offers construction, development, and operation of green field projects and wind power plants. The company offers services such as consultancy services, administration, financing, development, and management of wind farms. It also offe …
  • Haisco Pharmaceutical Group Co Ltd (002653)：製薬・医療：M&Aディール及び事業提携情報
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations. The company offers parenteral nutrition drugs, first-aid drugs, antibiotics, anesthetic agents, nervous system drugs, digestive sy …
  • Belfius Bank Sa
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆